The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2015 ACR/ARHP Annual Meeting: Research Lends Insight Into Osteoporosis Treatment, New Auto-Inflammatory Disease, Scleroderma

2015 ACR/ARHP Annual Meeting: Research Lends Insight Into Osteoporosis Treatment, New Auto-Inflammatory Disease, Scleroderma

March 15, 2016 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

It’s the latest study to show the superiority of denosumab in patients who’ve previously been treated with bisphosphonates. Previous studies have compared the drug to risedronate, alendronate and ibandronate.1-4

You Might Also Like
  • 2015 ACR/ARHP Annual Meeting: Genetically Complex Auto-Inflammatory Diseases
  • 2015 ACR/ARHP Annual Meeting: Macrophage Polarization and Its Role in Inflammatory Disease
  • 2015 ACR/ARHP Annual Meeting: Cellular Triggers in Inflammatory Disease
Explore This Issue
March 2016
Also By This Author
  • Tech Talk: Apps Put More Rheumatology Information at Fingertips

“This study completes a suite of trials,” he said, “that shows transitioning from a bisphosphonate to DMAb provides greater increases in BMD (bone mineral density) and reduction in bone turnover markers compared to maintaining therapy with another bisphosphonate.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A20 Mutations

Dr. Zhou

Dr. Zhou

In another study, Qing Zhou, PhD, a researcher with the National Human Genome Research Institute of the National Institutes of Health, described a new auto-inflammatory disease involving mutations in the TNFAIP3 gene, which causes haploinsufficiency of the A20 anti-inflammatory protein.5

“The patient presents with a childhood onset of systemic inflammation and some features resemble Behçet’s disease,” Dr. Zhou said. The features include skin lesions, oral and genital ulcers, ocular inflammation, arthralgia and arthritis and GI inflammation. Researchers have called the disease HA20.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The work began with two families in whom A20 mutations were found with exome sequencing, which led to the screening of 150 other patients with similar clinical features.

Those with the A20 mutations, researchers found, do not inhibit tumor necrosis factor-induced activation of the NF-kB inflammatory pathway. And there is an overproduction of inflammatory cytokines—such as IL-1-beta, tumor necrosis factor and IL-6—in these patients, they found.

These A20 mutations activate the NLRP3 inflammasome, which has been recognized as the body’s most influential and versatile signaling platform for inflammatory disorders.6

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

There have been positive, though early, results using an agent targeting IL-1-beta, Dr. Zhou said.

“These findings raise the possibility of new targeted therapies for this spectrum of disease,” she said.

Opportunity for Scleroderma Treatment

In other findings, Raymond Ong Jr., a researcher at Singapore General Hospital, described new insights into the interplay between the microenvironment of the skin and the periphery in scleroderma that might provide an opportunity for treatment.

Mr. Ong

Mr. Ong

In scleroderma (SSc), he said, there is an unmet need to identify and describe immune cell phenotypes that are involved in scleroderma pathogenesis to drive development of targeted therapies.

In this trial, he said, researchers hypothesized that immune signatures found at the interface of the microenvironment and systemic immunity both define disease pathogenesis and dictate outcomes in scleroderma patients.

Researchers employed an array of “high throughput” technologies to study 23 subjects—including scleroderma subjects and healthy controls—in search of immune signatures clustered meaningfully at the level of single cells. They used gene expression studies with human dermal fibroblasts stimulated with an autoantigen (Topo I) that’s linked with SSc; mass spectrometry analysis of peripheral blood; and RNA sequence analysis.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Scleroderma, Systemic Inflammatory Syndromes Tagged With: 2015 ACR/ARHP Annual Meeting, American College of Rheumatology, auto-inflammatory disease, Bisphosphonate, Immunology, Osteoporosis, Research, Scleroderma, TreatmentIssue: March 2016

You Might Also Like:
  • 2015 ACR/ARHP Annual Meeting: Genetically Complex Auto-Inflammatory Diseases
  • 2015 ACR/ARHP Annual Meeting: Macrophage Polarization and Its Role in Inflammatory Disease
  • 2015 ACR/ARHP Annual Meeting: Cellular Triggers in Inflammatory Disease
  • 2015 ACR/ARHP Annual Meeting: Therapies that Target Schnurri-3 Hold Promise for Osteoporosis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.